Ashkon Software

   







 


CFRXZ - ContraFect Corporation

ContraFect Corporation logo CFRXZ is the stock ticker symbol for ContraFect Corporation's Series 2 warrants. ContraFect Corporation is a clinical-stage biotechnology company that focuses on the discovery and development of novel protein and antibody therapeutics for the treatment of life-threatening bacterial infections.

As of September 2021, ContraFect's lead product candidate is exebacase, which is a recombinant protein that targets and destroys certain types of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Exebacase has completed Phase 2 clinical trials for the treatment of MRSA bacteremia, and the company is currently conducting Phase 3 clinical trials for this indication.

ContraFect's pipeline also includes a range of other product candidates that are in various stages of development, including CF-370, which is a potent lysin that targets Streptococcus pneumoniae, and CF-405, which is a potent lysin that targets Pseudomonas aeruginosa.

As a clinical-stage biotechnology company, ContraFect's success will depend on its ability to successfully develop and commercialize its product candidates, which can be a long and uncertain process. The company also faces competition from other companies that are developing treatments for bacterial infections.

Investors who are considering investing in ContraFect should carefully evaluate the company's financial position, its product pipeline, and the competitive landscape. Additionally, investing in clinical-stage biotechnology companies like ContraFect can be highly risky, and investors should be prepared for the possibility of significant volatility and potent

 



 

 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer